Sign up
Pharma Capital

'Pivotal' year ahead for Allergy Therapeutics with key trial readouts

Nick Wykeman and Manuel Llobet from Allergy Therapeutics plc (LON:AGY) caught up with Proactive Investors following the release of their interim results.

Allergy's continued to gain market share as it heads into a ‘pivotal’ twelve months.

Interim revenues rose by 4% to £42.2mln despite the pollen season being described as ‘abnormally weak’.

Headline or first glance data from the Phase III Pollinex Quattro Birch study in Europe is expected in the second half of the year along with first results from a Grass MATA MPL Phase II trial.

 

View full AGY profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.